TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Regeneus Ltd. ( (AU:CMB) ) just unveiled an update.
Cambium Bio Limited has made significant progress in its Phase 3 trials for Elate Ocular®, a treatment for dry eye disease, with ethics approvals obtained in both Australia and the United States. The company is preparing for patient dosing after satisfying FDA requirements and has secured additional funding to support its clinical operations. The financial report highlights a disciplined approach to managing costs, with a focus on research and development, while maintaining a conservative cash balance to achieve near-term milestones.
More about Regeneus Ltd.
Cambium Bio Limited is a clinical-stage regenerative medicine company focusing on developing innovative biologics for ophthalmology and tissue repair applications.
Average Trading Volume: 10,284
Technical Sentiment Signal: Sell
Current Market Cap: A$5.85M
For an in-depth examination of CMB stock, go to TipRanks’ Overview page.